Effects of curcumin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen, in rats: Possible role of CYP3A4 and P-glycoprotein inhibition by curcumin

Pharmazie

Volumn 67, Issue 2, 2012, Pages 124-130

  Cho, Y A ^a   Lee, W ^b   Choi, Jun Shik ^b  

^a Gyeongsang National University School of Medicine   (South Korea)

^b Chosun University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AFIMOXIFENE; CURCUMIN; CYTOCHROME P450 3A4; GLYCOPROTEIN P; RHODAMINE 123; TAMOXIFEN; 4-HYDROXYTAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CYTOCHROME P 450 3A4, RAT; CYTOCHROME P-450 3A4, RAT; CYTOCHROME P450; DRUG DERIVATIVE; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; ERYTHROMYCIN ETHYLSUCCINATE; FLUORESCENT DYE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; FIRST PASS EFFECT; LIVER; MALE; NONHUMAN; RAT; SINGLE DRUG DOSE; SMALL INTESTINE; ANIMAL; AREA UNDER THE CURVE; BIOAVAILABILITY; BLOOD; DRUG ANTAGONISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CURCUMIN; CYTOCHROME P-450 ENZYME SYSTEM; ERYTHROMYCIN ETHYLSUCCINATE; FLUORESCENT DYES; HUMANS; INDICATORS AND REAGENTS; INJECTIONS, INTRAVENOUS; MALE; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY; RHODAMINE 123; TAMOXIFEN;

EID: 84860641851     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2012.1099     Document Type: Article

References (47)

1. Aggarwal BB, Shishodia S (2006) Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71: 1397-1421.
2. Appiah-Opong R, de Esch I, Commandeur JN, Andarini M, Vermeulen NP (2008) Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues. Eur J Med Chem 43: 1621-1631.
3. Bogaards JJ, Bertrand M, Jackson P, Oudshoorn MJ, Weaver RJ, van Bladeren PJ, Walther B (2000) Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 30: 1131-1152.
4. Borgna JL, Rochefort H (1981) Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. J Biol Chem 256: 859-868.
5. Buchanan CM, Buchanan NL, Edgar KJ, Little JL, Malcolm MO, Ruble KM, Wacher VJ, Wempe MF (2007) Pharmacokinetics of tamoxifen after intravenous and oral dosing of tamoxifen-hydroxybutenyl-beta-cyclodextrin formulations. J Pharm Sci 96: 644-660.
6. Buckley MT, Goa KL (1989) Tamoxifen: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Clin Pharmacokin 37: 451-490.
7. Cao X, Gibbs ST, Fang L, Miller HA, Landowski CP, Shin HC, Lennernas H, Zhong Y, Amidon GL, Yu LX, Sun D (2006) Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res 23: 1675-1686.
8. Choi H, Chun YS, Kim SW, Kim MS, Park JW (2006) Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition. Mol Pharmacol 70: 1664-1671.
9. Coezy E, Borgna JL, Rochefort H (1982) Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 42: 317-323.
10. Crespi CL, Miller VP, Penman BW (1997) Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem 248: 188-190.
11. Crewe HK, Ellis SW, Lennard MS, Tucker GT (1997) Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 53: 171-178.
12. Cummins CL, Jacobsen W, Benet LZ (2002) Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 300: 1036-1045.
13. Deshpande SS, Ingle AD, Maru GB (1998) Chemopreventive efficacy of curcumin-free aqueous turmeric extract in 7,12-dimethylbenz[a]anthracene-induced rat mammary tumorigenesis. Cancer Lett 123: 35-40.
14. Efferth T, Davey M, Olbrich A, Rücker G, Gebhart E, Davey R (2002) Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells. Blood Cells Mol Dis 28: 160-168.
15. Fornander T, Hellstrom AC, Moberger B (1993) Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Nat Cancer Inst 85: 1850-1855.
16. Freid KM, Wainer IW (1994) Direct determination of tamoxifen and its four major metabolites in plasma using coupled column high-performance liquid chromatography. J Chromatogr B Biomed Appl 655: 261-268.
17. Furr BJ, Jordan VC (1984) The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25: 127-205.
18. Gant TW, O'Connor CK, Corbitt R, Thorgeirsson U, Thorgeirsson SS (1995) In vivo induction of liver P-glycoprotein expression by xenobiotics in monkeys. Toxicol Appl Pharmacol 133: 269-276.
19. Govindarajan VS (1980) Turmeric-chemistry, technology, and quality. Crit Rev Food Sci Nutr 12: 199-301.
20. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ (1986) Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261: 5051-5060.
21. Huang MT, Lou YR, Ma W, Newmark HL, Reuhl KR, Conney AH (1994) Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res 54: 5841-5847.
22. Huang MT, Newmark HL, Frenkel K (1997) Inhibitory effects of curcumin on tumorigenesis in mice. J Cell Biochem 27: 26-34.
23. Jacolot F, Simon I, Dreano Y, Beaune P, Riche C, Berthou F (1991) Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem Pharmacol 41: 1911-1919.
24. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN (1995) Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 13: 513-529.
25. Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, Desta Z, Flockhart DA, Skaar TC (2004) Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85: 151-9.
26. Kaminsky LS, Fasco MJ (1991) Small intestinal cytochromes P450. Crit Rev Toxocol 21: 407-422.
27. Kelly PA, Wang H, Napoli KL, Kahan BD, Strobel HW (1999) Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4. Eur J Drug Metab Pharmacokinet 24: 321-328.
28. Kim CS, Choi SJ, Park CY, Li C, Choi JS (2010) Effects of silybinin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen in rats. Anticancer Res 30: 79-85.
29. Lewis DFV (1996) Cytochrome P450. Substrate specificity and metabolism. In: Cytochromes P450. Structure, Function, and Mechanism. Taylor & Francis: Bristol., pp. 122-123.
30. Mani C, Gelboin HV, Park SS, Pearce R, Parkinson A, Kupfer D (1993) Metabolism of the antimammary cancer antiestrogenic agent tamoxifentamoxifen. I. Cytochrome P450-catalysed N-demethylation and 4-hydroxylation. Drug Metab Dispos 21: 645-656.
31. Meier CR, Jick H (1998) Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 45: 608-612.
32. Park WC, Jordan VC (2002) Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention. Trends Mol Med 8: 82-88.
33. Rao CV, Rivenson A, Simi B, Reddy BS (1995) Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res 55: 259-266.
34. Rao US, Fine RL, Scarborough GA (1994) Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol 48: 287-292.
35. Shin SC, Choi JS (2009) Effects of epigallocatechin gallate on the oral bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats. Anti-Cancer Drugs 20: 584-588.
36. Shin SC, Choi JS, Li X (2006) Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. Int J Pharm 313: 144-149.
37. Shukla PK, Khanna VK, Ali MM, Khan MY, Srimal RC (2008) Anti-ischemic effect of curcumin in rat brain. Neurochem Res 33: 1036-1043.
38. Singh SV, Hu X, Srivastava SK, Singh M, Xia H, Orchard JL, Zaren HA (1998) Mechanism of inhibition of benzo[a]pyrene-induced forestomach cancer in mice by dietary curcumin. Carcinogenesis 19: 1357-1360.
39. Singletary K, MacDonald C, Iovinelli M, Fisher C, Wallig M (1998) Effect of the beta-diketones diferuloylmethane (curcumin) and dibenzoylmethane on rat mammary DNA adducts and tumors induced by 7,12-dimethylbenz[a]anthracene. Carcinogenesis 19: 1039-1043.
40. Srivastava KC, Bordia A, Verma SK (1995) Curcumin, a major component of food spice turmeric (Curcuma longa) inhibits aggregation and alters eicosanoid metabolism in human blood platelets. Prostaglandins Leukot Essent Fatty Acids 52: 223-227.
41. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95: 1758-1764.
42. Sutherland L, Ebner T, Burchell B (1993) The expression of UDP-glucuronosyltransferases of the UGT1 family in human liver and kidney and in response to drugs. Biochem Pharmacol 45: 295-301.
43. Tanaka T, Makita H, Ohnishi M, Hirose Y, Wang A, Mori H, Satoh K, Hara A, Ogawa H (1994) Chemoprevention of 4-nitroquinoline 1-oxide-induced oral carcinogenesis by dietary curcumin and hesperidin: comparison with the protective effect of beta-carotene. Cancer Res 54: 4653-4659.
44. Thapliyal R, Maru GB (2001) Inhibition of cytochrome P450 isozymes by curcumins in vitro and in vivo. Food Chem Toxicol 39: 541-547.
45. Turgeon D, Carrier JS, Lévesque E, Hum DW, Bélanger A (2001) Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 142: 778-787.
46. Wacher VJ, Wu CY, Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13: 129-134.
47. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57: 1439-1443.